IBSPOT.com Inc.
2 extracted findings · 2 model-assigned issue types
FDA source excerpt, selected passage
FDA confirmed through laboratory analyses that “Taoscare Motion Sickness Patch” and “Navabelle Motion Sickness Patches” purchased on www.ibspot.com contained the ingredients diphenhydramine, diphenhydramine N-oxide, and diclofenac, which are not listed on the product labels.
Findings and supporting evidence
Model-assisted readings, not an exhaustive interpretation. Compare with the extracted source findings below.
Products contained undeclared active ingredients, making them misbranded under section 502(a).
Supporting FDA text
Source excerpt · automated text-match checkFDA confirmed through laboratory analyses that “Taoscare Motion Sickness Patch” and “Navabelle Motion Sickness Patches” purchased on www.ibspot.com contained the ingredients diphenhydramine, diphenhydramine N-oxide, and diclofenac, which are not listed on the product labels.
Products are unapproved new drugs marketed without FDA-approved applications, violating FD&C Act sections 301(d) and 505(a).
Supporting FDA text
Source excerpt · automated text-match checkNo FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, these products are unapproved new drugs and the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).
Findings extracted from the letter
Selected FDA passages, not the complete letter.
Source passage selected by the model
Source passage selected by the model
What FDA requested
Model-assisted summary. Consult the letter for complete requests and conditions.
- Notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps taken to correct any violations, including an explanation of each step being taken to prevent recurrence and copies of related documentation.
- If the products are believed not to be in violation, include reasoning and supporting information.
- If corrective action cannot be completed within fifteen working days, state the reason for the delay and the time within which correction will be completed.
Sections and clauses cited
As cited in this historical letter, not a statement of current regulatory requirements.